Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells

Journal of Immunology

Volumn 173, Issue 11, 2004, Pages 6654-6659

  Reich Zeliger, Shlomit ^a   Bachar Lustig, Esther ^a   Gan, Judith ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL ACTIVITY; CELL CONTACT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DILUTION; EFFECTOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; LYMPHOCYTE SUBPOPULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENE; TRANSGENIC MOUSE; TRANSPLANTATION TOLERANCE;

EID: 9144266371     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.11.6654     Document Type: Article

References (57)

1. Martelli, M. F., F. Aversa, E. Bachar-Lustig, A. Velardi, S. Reich-Zeliger, A. Tabilio, H. Gur, and Y. Reisner. 2002. Transplants across human leukocyte antigen barriers. Semin. Hematol. 39:48.
2. Einsele, H. M. H., and M. D. Holger. 2002. Cellular immunity to viral and fungal antigens after stem cell transplantation. Curr. Opin. Hematol. 9:485.
3. Komanduri, K. 2002. Thymic function and allogeneic T-cell responses in stem-cell transplantation. Cytotherapy 4:333.
4. Hogan, W. J., and R. Storb. 2003. Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease. Immunol. Res. 28:1.
5. Giralt, S. 2002. Update on non-myeloablative stem cell transplantation for hematologic malignancies. Int. J. Hematol. 76:368.
6. Slavin, S. 2002. Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and non-malignant diseases and towards transplantation of organ allografts. Transplant. Proc. 34:3371.
7. Maloney, D. G., B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru. 2002. Non-myeloablative transplantation. Hematology 2002:392.
8. Miller, R. G. 1980. An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature 287:544.
9. Miller, R. G. 1980. Lymphoid suppressor cells. In Strategies of Immune Regulation. E. E. Sercarz and A. J. Cunningham, eds. Academic Press, New York, p. 507.
10. Miller, R. G., and H. R. Derry. 1979. A cell population in nu/nu spleen can prevent generation of cytotoxic lymphocytes by normal spleen cells against self antigens of the nu/nu spleen. J. Immunol. 122:1502.
11. Muraoka, S., and R. G. Miller. 1980. Cells in bone marrow and in T cell colonies grown from bone marrow can suppress generation of cytotoxic T lymphocytes directed against their self antigens. J. Exp. Med. 152:54.
12. Fink, P. J., R. P. Shimonkevitz, and M. J. Bevan. 1988. Veto cells. Annu. Rev. Immunol. 6:115.
13. Claesson, M. H., and C. Ropke. 1986. Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures. Curr. Top. Microbiol. Immunol. 126:213.
14. Claesson, M. H., and R. G. Miller. 1984. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. I. CTL clones express strong anti-self suppressive activity. J. Exp. Med. 160:1702.
15. Cassell, D. J., and J. Forman. 1990. Regulation of the cytotoxic T lymphocyte response against Qa-1 alloantigens. J. Immunol. 144:4075.
16. + antigen-specific T cells after in vivo exposure to male antigen. J. Immunol. 148:3740.
17. Tscherning, T., and M. H. Claesson. 1993. Veto suppression: the peripheral way of T cell tolerization. Exp. Clin. Immunogenet. 10:179.
18. Sambhara, S. R., and R. G. Miller. 1991. Programmed cell death of T cells signaled by the T cell receptor and the α3 domain of class I MHC. Science 252:1424.
19. + cells whose class I MHC can bind the peptide. J. Immunol. 152:1103.
20. Claesson, M. H. 1987. Veto cell H-2 antigens: veto cell activity is restricted by determinants encoded by K, D, and I MHC regions. Cell. Immunol. 109:360.
21. Hiruma, K., H. Nakamura, P. A. Henkart, and R. E. Gress. 1992. Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes. J. Exp. Med. 175:863.
22. + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J. Immunol. 157:4811.
23. Chrobak, P., and R. E. Gress. 2001. Veto activity of activated bone marrow does not require perform and Fas ligand. Cell Immunol. 208:80.
24. Hiruma, K., and R. E. Gress. 1992. Cyclosporine A and peripheral tolerance: inhibition of veto cell-mediated clonal deletion of postthymic precursor cytotoxic T lymphocytes. J. Immunol. 149:1539.
25. Bachar-Lustig, E., S. Reich-Zeliger, and Y. Reisner. 2003. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 102:1943.
26. Van Oostveldt, K., H. Dosogne, C. Burvenich, M. J. Paape, V. Brochez, and E. Van den Eeckhout. 1999. Flow cytometric procedure to detect apoptosis of bovine polymorphonuclear leukocytes in blood. Vet. Immunol. Immunopathol. 70:125.
27. Schutte, B., R. Nuydens, H. Geerts, and F. Ramaekers. 1998. Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J. Neurosci. Methods 86:63.
28. Span, L. F., A. H. Pennings, G. Vierwinden, J. B. Boezeman, R. A. Raymakers, and T. de Witte. 2002. The dynamic process of apoptosis analyzed by flow cytometry using annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry 47:24.
29. Rachamim, N., J. Gan, H. Segall, R. Krauthgamer, H. Marcus, A. Berrebi, M. Martelli, and Y. Reisner. 1998. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65:1386.
30. Burlingham, W. J., A. P. Grailer, J. H. Fechner, Jr., S. Kusaka, M. Trucco, M. Kocova, F. O. Belzer, and H. W. Sollinger. 1995. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 59:1147.
31. Thomas, J. M., F. M. Carver, J. Kasten-Jolly, C. E. Haisch, L. M. Rebellato, U. Gross, S. J. Vore, and F. T. Thomas. 1994. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 57:101.
32. Uberti, J., F. Martilotti, T. H. Chou, and J. Kaplan. 1992. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation. Blood 79:261.
33. Ogasawara, M., K. Iwabuchi, R. A. Good, and K. Onoe. 1988. Bone marrow cells from allogeneic bone marrow chimeras inhibit the generation of cytotoxic lymphocyte responses against both donor and recipient cells. J. Immunol. 141:3306.
34. + CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 13:507.
35. 1 T cells. Blood 94:3212.
36. Muraoka, S. 1990. Induction of linked suppression in addition to the donor H-2 class I-specific unresponsiveness in recipient T cells by transfusing class I plus class II-disparate, but not class I alone-disparate, bone marrow cells. Cell. Immunol. 128:261.
37. O'Connell, P. J., and W. J. Burlingham. 1999. Donor dendritic cell persistence in organ allograft recipients in the absence of immunosuppression. J. Leukocyte Biol. 66:301.
38. + stem cells: a new option for leukemia patients without an HLA-matched donor. Curr. Opin. Immunol. 12:536.
39. Carreno, M. R., L. Fuller, J. M. Mathew, G. Ciancio, G. W. Burke, V. Esquenazi, C. Ricordi, A. G. Tzakis, and J. Miller. 2003. Human donor bone marrow cells induce in vitro "suppressor T cells" that functionally suppress autologous B cells. Hum. Immunol. 64:21.
40. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196:1099.
41. Mathew, J. M., L. Fuller, M. Carreno, R. Garcia-Morales, G. W. Burke III, C. Ricordi, V. Esquenazi, A. G. Tzakis, and J. Miller. 2000. Involvement of multiple subpopulations of human bone marrow cells in the regulation of allogeneic cellular immune responses. Transplantation 70:1752.
42. Lapidot, T., I. Lubin, A. Terenzi, Y. Faktorowich, P. Erlich, and Y. Reisner. 1990. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc. Natl. Acad. Sci. USA 87:4595.
43. + thymocytes. Blood 80:2406.
44. Sheng-Tanner, X. F., and R. G. Miller. 1994. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation: role of class I and class II major histocompatibility complex. Transplantation 57:1081.
45. Ernst, B., D. S. Lee, J. M. Chang, J. Sprent, and C. D. Surh. 1999. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11:173.
46. + T cells in lymphopenic hosts. Immunity 11:183.
47. Wu, Z., S. J. Bensinger, J. Zhang, C. Chen, X. Yuan, X. Huang, J. F. Markmann, A. Kassaee, B. R. Rosengard, W. W. Hancock, et al. 2004. Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. 10:87.
48. Martin, P. J. 1993. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J. Exp. Med. 178:703.
49. Velardi, A., L. Ruggeri, A. Moretta, and L. Moretta. 2002. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 23:438.
50. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097.
51. Ruggeri, L., M. Capanni, M. Casucci, I. Volpi, A. Tosti, K. Perruccio, E. Urbani, R. S. Negrin, M. F. Martelli, and A. Velardi. 1999. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333.
52. Silva, M. R., A. Parreira, and J. L. Ascensao. 1995. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp. Hematol. 23:1676.
53. + cytotoxic cells from human umbilical cord blood. Exp. Hematol. 29:104.
54. Tam, Y. K., J. A. Martinson, K. Doligosa, and H. G. Klingemann. 2003. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5:259.
55. - natural killer T cells specific for MUC1 mucin. Cancer Res. 64:1171.
56. Godfrey, W. R., M. R. Krampf, P. A. Taylor, and B. R. Blazar. 2004. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103:1158.
57. Fehse, B., M. Goldmann, O. Frerk, M. Bulduk, and A. R. Zander. 2000. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant. 25(Suppl. 2):S39.